HB8794, the “Fostering Effective Diagnosis and Treatment for Underserved Populations with Bleeding Disorders Act of 2026” or the “FED UP with Bleeding Disorders Act of 2026,” is a federal health bill focused on improving the recognition, diagnosis, treatment, and public awareness of bleeding disorders in women and girls. The bill’s findings emphasize that many women with bleeding disorders remain undiagnosed for years, that delayed diagnosis can lead to serious health consequences, and that better care can reduce complications, including during pregnancy and childbirth. It also highlights the role of specialized hemophilia treatment centers and the need to include women and girls more fully in clinical research.
The bill directs the Secretary of Health and Human Services to conduct an interagency review of federal programs, research, training, access to care, and strategic plans related to bleeding disorders in women and girls. That review must examine the state of the science, provider education, access barriers in rural and underserved areas, and the inclusion of women and girls in clinical research, and it must result in a report to Congress and be posted publicly. The Secretary must also solicit public comments, especially from patients, advocacy organizations, and federally funded research entities.
After the report is completed, the bill requires HHS to launch a nationwide, evidence-based public education and awareness campaign aimed at women and girls and at health care providers such as school nurses, pediatricians, OB-GYNs, family physicians, and hematologists. The campaign must be designed to reach rural and underserved communities, include culturally and linguistically appropriate materials, and distribute information to schools, medical schools, public health departments, and health care facilities. The bill authorizes $10 million annually for fiscal years 2027 through 2031 to carry out the awareness campaign.
The bill’s impact would be to create new federal review, reporting, and outreach obligations within HHS and to encourage coordination among agencies including CMS, HRSA, CDC, NIH, VA, the Defense Health Agency, and FDA. It would not directly amend existing state laws, but it could influence clinical practice, public health messaging, and federal research priorities affecting hemophilia, von Willebrand disease, rare factor deficiencies, and maternal health care. It also could affect how providers identify and manage heavy menstrual bleeding, pregnancy-related bleeding risks, and other symptoms in underserved populations.
There is no recorded committee debate or vote history in the provided context, so no formal sentiment can be derived from floor or committee action. Based on the bill text, the measure appears broadly supportive of expanded research, education, and access to care, with an emphasis on women and girls who have historically been underdiagnosed. Potential points of contention, if raised, would likely involve the cost of the authorized appropriation, the scope of federal involvement in health education and research coordination, and how the campaign and review would be implemented across multiple agencies and provider settings.
HB8794 would create new federal duties for the Secretary of Health and Human Services to review and update programs related to bleeding disorders in women and girls, report findings to Congress, and coordinate across multiple federal health and research agencies. It also authorizes $10 million per year from FY2027 through FY2031 for a national awareness campaign. The bill does not directly change state statutes, but it could affect state and local public health efforts, provider education, and access to specialized care by shaping federal guidance, research priorities, and outreach materials.
No votes or committee transcripts were provided, so there is no recorded legislative sentiment from debate or roll call. The bill’s text reflects a strongly supportive posture toward expanding diagnosis, treatment, and awareness for a population described as underserved and underdiagnosed. Overall, the measure appears noncontroversial in purpose, though its funding level and federal coordination requirements could draw scrutiny if the bill advances.
The bill itself does not present explicit partisan or policy conflict, and no committee discussion is available to identify objections. If contested, likely issues would include the $50 million total authorization over five fiscal years, whether HHS should lead a multi-agency review, and how to ensure the campaign reaches rural and underserved communities effectively. Another possible point of discussion is the bill’s focus on women and girls, including the inclusion of pregnancy, menstruation, and fertility-related concerns in bleeding disorder research and education.